Hepatitis C Virus NS5A Inhibitor [EPC] — Patent Landscape

Aggregated US Orange Book patent estate across every drug in the hepatitis c virus ns5a inhibitor [epc] class. 38 active patents protecting 2 drugs. First major cliff: 2030. Daily refresh.

2
Drugs in class
38
Active US patents
54/100
Avg vulnerability
—
Annual revenue covered

Originators

AbbVie 36 patents Merck & Co. 2 patents

Cliff calendar — next 15 years

1
29
10
30
3
31
8
32
6
34
8
35
2
36

Drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Mavyret
GLECAPREVIR
 AbbVie 36 40 — 2030-06-10
Zepatier
ELBASVIR
 Merck & Co. 2 68 — 2029-07-24

Most attackable patents

Patent Drug Type Vuln Expiry
7973040 Zepatier method of use 68 2029-07-24
8871759 Zepatier method of use 68 2031-05-04
11484534 Mavyret method of use 53 2034-03-14
10039754 Mavyret method of use 51 2030-06-10
10028937 Mavyret method of use 51 2030-06-10
10028937 Mavyret method of use 51 2030-06-10
10039754 Mavyret method of use 51 2030-06-10
9586978 Mavyret method of use 51 2030-11-06
9586978 Mavyret method of use 51 2030-11-06
10028937 Mavyret other 51 2030-12-10

Strongest defences

Patent Drug Type Vuln Expiry
9321807 Mavyret composition of matter 0 2035-06-05
9321807 Mavyret composition of matter 0 2035-06-05
RE48923 Mavyret composition of matter 0 2035-05-08
RE48923 Mavyret composition of matter 0 2035-05-08
8937150 Mavyret composition of matter 0 2032-05-18
8937150 Mavyret composition of matter 0 2032-05-18
11246866 Mavyret formulation 33 2036-06-24
11246866 Mavyret other 45 2036-12-24
9321807 Mavyret other 45 2035-12-05
9321807 Mavyret other 45 2035-12-05

Related